Nkarta, Inc.

Nkarta, Inc.

NKTXNYSE / NASDAQHealthcareSmall cap

$1.13+$0.01 (+1.3%)

Last close · Data as of Nov 20, 2026

Market cap
$198.2M
Revenue
$0.00
ROCE
-39.1%

-34.4% over the last year

Nkarta, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-34.8%
3M
-54.0%
6M
-59.5%
1Y
-34.4%
5Y
Hidden
  • This period includes a one-day price step on 17 Oct 2023 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

52-week range

Day change +$0.01 (+1.3%) from $1.12 to $1.13 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in NKTX, bought on each weekday since 2021.

News & filings

What Nkarta filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 104 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are more than ten times current liabilities.
  • Revenue is too small for margins and growth rates to be read, so those points are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment.

Read moreShow less

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Sector
Healthcare
Shares outstanding
71.1M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$198.2M
P/B
0.6x
52-week high
$3.67
52-week low
$1.12

Profitability

ROE
-33.3%
ROCE
-39.1%
ROIC
-27.6%
ROA
-25.7%

Growth

Revenue
$0.00
Net profit growth, 1Y
-4.3%
Free cash flow
-$89.9M

Solvency

Current ratio
12.69
Debt / Equity
0.24
Debt / Assets
0.19
CFO / Net profit
0.85
Cash / Market cap
139.4%

Revenue and net profit

Annual revenue, with net profit as the dashed line.

Nkarta, Inc. revenue and net profit by fiscal year
Nkarta, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$0.00-$113.8M
FY2023$0.00-$117.5M
FY2024$0.00-$108.8M
FY2025$0.00-$104.1M

Cash flows

FY2025: -$88.7M from operations, -$89.9M free after investment (dashed).

Nkarta, Inc. operating and free cash flow by fiscal year
Nkarta, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$57.0M-$104.1M
FY2023-$86.2M-$114.3M
FY2024-$99.7M-$104.1M
FY2025-$88.7M-$89.9M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$0.00
EBITDA
-$112.8M
Net profit
-$104.1M
Cash from operations
-$88.7M
Free cash flow
-$89.9M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$0.00-$112.8M-$104.1M-$89.9M-33.3%—-4.3%

Monthly returns

Month-by-month returns of NKTX across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$404.2M
Liabilities$91.9M
Equity$312.3M
Paid-in capital$960.2M
Retained earnings-$648.3M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; NKTX highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

Not shown (no positive earnings and no EV / Sales): Nkarta, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Nkarta, Inc.NKTXthis company$198.2M—0.6x-33.3%—
Accendra Health, Inc.ACH$202.9M-0.2x-0.4x238.8%9.3x
Sanara MedTech Inc.SMTI$202.7M-5.4x34.1x-632.5%22.7x
TriSalus Life Sciences, Inc.TLSI$202.7M-5.2x-6.0x115.8%-6.6x
Embecta Corp.EMBC$202.3M2.1x-0.3x-14.6%4.9x
Alector, Inc.ALEC$201.0M—6.6x-466.3%—
Anika Therapeutics, Inc.ANIK$196.8M-18.1x1.4x-7.6%-31.1x
Lucid Diagnostics Inc.LUCD$194.6M—17.8x-645.1%—
Cartesian Therapeutics, Inc.RNAC$192.4M-1.5x-1.5x103.2%-1.0x
Peer median—-3.3x0.5x-11.1%2.0x

Year-to-date ROI

NKTX since 1 January, against earlier years.

Historical volatility

NKTX's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

LineFY2025
Operating expensesOperating Expense$122.0M
Research and developmentResearch And Development$90.4M
Total expensesTotal Expenses$122.0M
Pretax incomePretax Income-$104.1M

Learn while you research

Academy chapters picked for Nkarta, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →